Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
VanEck Semiconductor ETF
SMH
The Technology Select Sector SPDR® Fund
XLK
4
Invesco Solar ETF
TAN
5
Invesco DB Commodity Index Tracking Fund
DBC
HK Stock MarketDetailed Quotes
ZAI LAB (09688)
- 15.080
- -0.360-2.33%
15min DelayMarket Closed May 13 16:08 CST
17.10BMarket Cap-12.25P/E (TTM)
15.400High14.940Low8.04MVolume15.400Open15.440Prev Close120.99MTurnover0.71%Turnover RatioLossP/E (Static)1.13BShares35.50052wk High3.30P/B17.10BFloat Cap12.31052wk Low--Dividend TTM1.13BShs Float151.200Historical High--Dividend LFY2.98%Range %10.560Historical Low15.056Avg Price100Lot Size--Div Yield TTM--Div Yield LFY
09688 Stock Chart
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
09688 Orderflow
Unit: --
09688 Orderflow Trend
IntradayDayWeekMonth
No Data
ZAI LAB (09688) News
U.S. Stock Movement | Zai Lab (ZLAB.US) Surged Over 10% as Zoci Granted FDA Fast Track Designation
On Monday, Zai Lab (ZLAB.US) surged over 10%, closing at $20.50.
Express News | Zai Lab Shares Are Trading Higher After the Company Announced That the FDA Granted It Fast Track Designation to Zocilurtatug Pelitecan for the Treatment of Extrapulmonary Neuroendocrine Carcinomas Following Progression After Standard First-line Therapy
The FDA Grants Fast Track Designation To Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) for Extrapulmonary Neuroendocrine Carcinomas Following Progression After Standard First-Line Therapy
Express News | Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a Dll3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (Epnecs)
UBS Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)
Express News | Citigroup Maintains Buy on Zai Lab, Lowers Price Target to $44
ZAI LAB (09688) Stock Forum
$Zai Lab (ZLAB.US)$
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
by Business Wire
Follow
- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need
- Preliminary clinical data recently presented at the AACR Annual Meeting suggest zoci has potential to be a first-in-class therapy for epNECs
- Zoc...
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
by Business Wire
Follow
- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need
- Preliminary clinical data recently presented at the AACR Annual Meeting suggest zoci has potential to be a first-in-class therapy for epNECs
- Zoc...
1
$Zai Lab (ZLAB.US)$
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
by Globe Newswire
Follow
Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Phase Ib/II study will test the combination of obrixtamig, a DLL3/CD3 T‑cell en...
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
by Globe Newswire
Follow
Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Phase Ib/II study will test the combination of obrixtamig, a DLL3/CD3 T‑cell en...
1
$Zai Lab (ZLAB.US)$ So rubbish…
$ZAI LAB (09688.HK)$
why are people selling when results will be out today?
why are people selling when results will be out today?
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)